[go: up one dir, main page]

EA200300815A1 - Способ клеточной терапии для лечения опухолей - Google Patents

Способ клеточной терапии для лечения опухолей

Info

Publication number
EA200300815A1
EA200300815A1 EA200300815A EA200300815A EA200300815A1 EA 200300815 A1 EA200300815 A1 EA 200300815A1 EA 200300815 A EA200300815 A EA 200300815A EA 200300815 A EA200300815 A EA 200300815A EA 200300815 A1 EA200300815 A1 EA 200300815A1
Authority
EA
Eurasian Patent Office
Prior art keywords
cells
antigen
treatment
responses
specific
Prior art date
Application number
EA200300815A
Other languages
English (en)
Other versions
EA013944B1 (ru
Inventor
Джули Дегро
Энн Мориарти
Дидье Дж. Летюрк
Майкл Р. Джексон
Пер А. Питерсон
Марджа Хейскала
Original Assignee
Орто-Макнейл Фармасьютикал, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Орто-Макнейл Фармасьютикал, Инк. filed Critical Орто-Макнейл Фармасьютикал, Инк.
Publication of EA200300815A1 publication Critical patent/EA200300815A1/ru
Publication of EA013944B1 publication Critical patent/EA013944B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4271—Melanoma antigens
    • A61K40/4272—Melan-A/MART
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/52—Genes encoding for enzymes or proenzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0601—Invertebrate cells or tissues, e.g. insect cells; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5156—Animal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A61K2039/55527—Interleukins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A61K2039/55527—Interleukins
    • A61K2039/55533—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A61K2039/55527—Interleukins
    • A61K2039/55538—IL-12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/515—CD3, T-cell receptor complex
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/99—Coculture with; Conditioned medium produced by genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Mycology (AREA)

Abstract

Т-клеточные реакции часто снижаются у людей с ослабленной иммунной системой. Авторы разработали способ выделения, стимуляции и размножения "наивных" цитотоксических Т-лимфоцитарных (ЦТЛ) предшественников антигенспецифичных эффекторов, способных лизировать опухолевые клетки in vivo. Такая ex vivo процедура дает полностью функциональные эффекторы. Искусственные антигенпрезентирующие клетки (нпАПК; Drosophila melanogaster) трансфицировали HLA класса I человека и определили вспомогательные молекулы, которые используются для стимуляции CD8+ Т-клеток у нормальных доноров и у раковых больных. Молекулы класса I, экспрессируемые с высокой плотностью на поверхности клеток Drosophila, являются пустыми, это позволяет эффективно нагрузить их множеством пептидов, что приводит к генерированию поликлональных ответов, распознающих опухолевые клетки, эндогенно экспрессирующие специфические пептиды. Генерируемые ответы являются сильными, антигенспецифичными и воспроизводимыми, если пептидный эпитоп представляет собой идентифицированный иммуноген. Такая искусственная система экспрессии антигена может быть адаптирована для лечения большинства видов рака у значительной части населения.Отчет о международном поиске был опубликован 2003.02.13.
EA200300815A 2001-02-20 2002-02-19 Способ получения неприродной антигенпрезентирующей клеточной линии и применение линии для лечения опухолей EA013944B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US27025201P 2001-02-20 2001-02-20
PCT/US2002/005748 WO2002065992A2 (en) 2001-02-20 2002-02-19 A cell therapy method for the treatment of tumors

Publications (2)

Publication Number Publication Date
EA200300815A1 true EA200300815A1 (ru) 2004-06-24
EA013944B1 EA013944B1 (ru) 2010-08-30

Family

ID=23030546

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200300815A EA013944B1 (ru) 2001-02-20 2002-02-19 Способ получения неприродной антигенпрезентирующей клеточной линии и применение линии для лечения опухолей

Country Status (21)

Country Link
US (2) US20030077248A1 (ru)
EP (3) EP2016930B1 (ru)
JP (3) JP2006510567A (ru)
KR (2) KR100971266B1 (ru)
CN (1) CN1571834B (ru)
AT (1) ATE396691T1 (ru)
BR (1) BR0207399A (ru)
CA (2) CA2438754C (ru)
DE (1) DE60226853D1 (ru)
DK (1) DK2016930T3 (ru)
EA (1) EA013944B1 (ru)
ES (2) ES2643582T3 (ru)
HU (1) HUP0402656A3 (ru)
IL (3) IL157366A0 (ru)
MX (1) MXPA03007503A (ru)
NO (1) NO334885B1 (ru)
NZ (1) NZ527683A (ru)
PL (1) PL206976B1 (ru)
PT (1) PT1377251E (ru)
WO (1) WO2002065992A2 (ru)
ZA (1) ZA200307327B (ru)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7973137B1 (en) 1996-03-28 2011-07-05 Johns Hopkins University Cell compositions comprising molecular complexes that modify immune responses
ATE396691T1 (de) 2001-02-20 2008-06-15 Ortho Mcneil Pharm Inc Zelltherapieverfahren für die behandlung von tumoren
US20040071671A1 (en) 2001-02-20 2004-04-15 Leturcq Didier J. Cell therapy method for the treatment of tumors
WO2002072766A2 (en) * 2001-03-09 2002-09-19 Board Of Regents, Universitx Of Texas System Induction of tumor immunity by variants of folate binding protein
EP1482963A4 (en) * 2002-03-08 2010-06-09 Univ Texas CONTROLLED MODULATION OF THE AMINO ACID SIDE CHAIN LENGTH OF PEPTIDE ANTIGEN
WO2004006951A1 (en) * 2002-07-12 2004-01-22 The Johns Hopkins University Reagents and methods for engaging unique clonotypic lymphocyte receptors
WO2004042041A1 (en) * 2002-11-07 2004-05-21 Johnson & Johnson Research Pty Limited A means of producing and utilising a population of disease specific cytotoxic t-lymphoctyes
EP1645183B1 (en) * 2003-06-16 2013-03-13 Kyushu University, National University Corporation Process for producing human-origin immunocompetent cell
JP2005139118A (ja) * 2003-11-07 2005-06-02 Ortho Mcneil Pharmaceut Inc 腫瘍の治療のための細胞治療方法
US20100094560A1 (en) * 2006-08-15 2010-04-15 Prometheus Laboratories Inc. Methods for diagnosing irritable bowel syndrome
US8129184B2 (en) 2006-09-26 2012-03-06 Cedars-Sinai Medical Center Cancer stem cell antigen vaccines and methods
WO2008039974A2 (en) 2006-09-28 2008-04-03 Cedars-Sinai Medical Center Cancer vaccines and vaccination methods
AU2007307206B2 (en) * 2006-10-04 2016-02-11 Janssen Pharmaceutica, N.V. Preparation of inactivated artificial antigen presenting cells and their use in cell therapies
WO2010028066A2 (en) 2008-09-02 2010-03-11 Cedars-Sinai Medical Center Cd133 epitopes
JP2010235611A (ja) * 2010-05-10 2010-10-21 Ortho Mcneil Pharmaceut Inc 腫瘍の治療のための細胞治療方法
US9029502B2 (en) 2010-12-20 2015-05-12 The Regents Of The University Of Michigan Inhibitors of the epidermal growth factor receptor-heat shock protein 90 binding interaction
CA2898474A1 (en) 2013-02-14 2014-08-21 Immunocellular Therapeutics, Ltd. Cancer vaccines and vaccination methods
CN103667189B (zh) * 2013-09-24 2015-10-28 上海宇研生物技术有限公司 用于治疗肺癌的cd8毒性t淋巴细胞及其制备方法
SG11201702191YA (en) * 2014-09-17 2017-04-27 Univ Johns Hopkins Reagents and methods for identifying, enriching, and/or expanding antigen-specific t cells
WO2016196506A1 (en) 2015-05-29 2016-12-08 Galena Biopharma, Inc. PEPTIDE VACCINE THERAPY FOR TREATMENT OF FRα-EXPRESSING TUMORS
EP3463438B1 (en) 2016-05-31 2022-04-06 The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. Vaccine therapy for treatment of endometrial and ovarian cancer
WO2017216768A1 (en) 2016-06-16 2017-12-21 Association For The Advancement Of Tissue Engineering And Cell Based Technologies And Therapies - A4Tec Dendrimer-derived artificial antigen, methods and uses thereof
EP3493836A4 (en) * 2016-08-02 2020-03-04 Nantcell, Inc. TRANSFECTION OF DENDRITIC CELLS AND RELATED METHODS
WO2025171250A1 (en) * 2024-02-08 2025-08-14 H. Lee Moffitt Cancer Center And Research Institute, Inc. Nyeso1 tcr for t-cell therapy and methods of use

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4530901A (en) 1980-01-08 1985-07-23 Biogen N.V. Recombinant DNA molecules and their use in producing human interferon-like polypeptides
US4401756A (en) 1981-04-14 1983-08-30 Immunex Corporation Process for preparing human interleukin 2
US4407945A (en) 1981-04-29 1983-10-04 Immunex Corporation Constitutive production of interleukin 2 by a T cell hybridoma
US4473642A (en) 1981-04-29 1984-09-25 Immunex Corporation Constitutive production of interleukin 2 by a T cell hybridoma
US6936694B1 (en) 1982-05-06 2005-08-30 Intermune, Inc. Manufacture and expression of large structural genes
US4992367A (en) 1986-05-12 1991-02-12 Hoffmann-La Roche Inc. Enhanced expression of human interleukin-2 in mammalian cells
US5229115A (en) 1990-07-26 1993-07-20 Immunex Corporation Adoptive immunotherapy with interleukin-7
US5637483A (en) 1991-10-04 1997-06-10 Whitehead Institute For Biomedical Research Irradiated tumor cell vaccine engineered to express GM-CSF
US5583031A (en) 1992-02-06 1996-12-10 President And Fellows Of Harvard College Empty major histocompatibility class II heterodimers
US5314813A (en) * 1992-02-19 1994-05-24 Scripps Research Institute Drosophila cell lines expressing genes encoding MHC class I antigens and B2-microglobulin and capable of assembling empty complexes and methods of making said cell lines
CA2069541C (en) 1992-05-26 2005-02-01 Cornelis J. M. Melief Induction of an antigen-specific t-lymphocyte response
US5397703A (en) 1992-07-09 1995-03-14 Cetus Oncology Corporation Method for generation of antibodies to cell surface molecules
US5662907A (en) 1992-08-07 1997-09-02 Cytel Corporation Induction of anti-tumor cytotoxic T lymphocytes in humans using synthetic peptide epitopes
US5487974A (en) 1992-12-22 1996-01-30 Ludwig Institute For Cancer-Research Method for detecting complexes containing human leukocyte antigen A2 (HLA-A2) molecules and a tyrosinase drived peptide on abnormal cells
US5801005A (en) 1993-03-17 1998-09-01 University Of Washington Immune reactivity to HER-2/neu protein for diagnosis of malignancies in which the HER-2/neu oncogene is associated
US5820866A (en) 1994-03-04 1998-10-13 National Jewish Center For Immunology And Respiratory Medicine Product and process for T cell regulation
US5585461A (en) * 1994-03-24 1996-12-17 Ludwig Institute For Cancer Research Isolated, MAGE-3 derived peptides which complex with HLA-A2 molecules and uses thereof
US5874560A (en) * 1994-04-22 1999-02-23 The United States Of America As Represented By The Department Of Health And Human Services Melanoma antigens and their use in diagnostic and therapeutic methods
US6017719A (en) 1994-06-14 2000-01-25 Nexell Therapeutics, Inc. Positive and positive/negative cell selection mediated by peptide release
US5595881A (en) 1994-08-09 1997-01-21 Anergen, Inc. Method for the detection of antigen presenting cells
US5827642A (en) 1994-08-31 1998-10-27 Fred Hutchinson Cancer Research Center Rapid expansion method ("REM") for in vitro propagation of T lymphocytes
US5843648A (en) 1995-01-10 1998-12-01 The United States Of America As Represented By The Secretary, Department Of Health And Human Services P15 and tyrosinase melanoma antigens and their use in diagnostic and therapeutic methods
US5645837A (en) 1995-01-17 1997-07-08 Thomas Jefferson University Peptides that inhibit T cell activation and methods of using the same
ATE240119T1 (de) * 1995-03-08 2003-05-15 Scripps Research Inst Antigen präsentierendes system und aktivierung von t-zellen
US5587289A (en) 1995-03-14 1996-12-24 Ludwig Institute For Cancer Research Isolated nucleic acid molecules which are members of the MAGE-Xp family and uses thereof
US5759783A (en) 1995-03-14 1998-06-02 Ludwig Institute For Cancer Research Method of screening for cancer by detecting messenger RNA for a MAGE-XP gene
US5695760A (en) 1995-04-24 1997-12-09 Boehringer Inglehiem Pharmaceuticals, Inc. Modified anti-ICAM-1 antibodies and their use in the treatment of inflammation
US5985270A (en) 1995-09-13 1999-11-16 Fordham University Adoptive immunotherapy using macrophages sensitized with heat shock protein-epitope complexes
WO1997032970A1 (en) 1996-03-04 1997-09-12 Targeted Genetics Corporation Modified rapid expansion methods ('modified-rem') for in vitro propagation of t lymphocytes
AU723355B2 (en) * 1996-05-23 2000-08-24 Scripps Research Institute, The MHC class II antigen presenting systems and methods for activating CD4+ T cells
AU2339299A (en) * 1998-01-26 1999-08-09 Dana-Farber Cancer Institute, Inc. Immune effector cell hybrids
WO1999054345A1 (en) 1998-04-21 1999-10-28 Thomas Jefferson University Cd8 antagonists
US6140050A (en) 1998-06-26 2000-10-31 Ludwig Institute For Cancer Research Methods for determining breast cancer and melanoma by assaying for a plurality of antigens associated therewith
US6913749B2 (en) 1998-11-02 2005-07-05 Resistentia Pharmaceuticals Ab Immunogenic polypeptides for inducing anti-self IgE responses
HK1041312B (en) 1999-04-16 2006-09-29 Ortho-Mcneil Pharmaceutical, Inc. Method for the detection of antigen specific t-cells
JP2001089389A (ja) 1999-07-22 2001-04-03 Sumitomo Pharmaceut Co Ltd 抗原特異的ｔ細胞の誘導剤
WO2001057068A1 (en) * 2000-02-01 2001-08-09 The Austin Research Institute Mucin-1 derived antigens and their use in immunotherapy
DE60130634T2 (de) * 2000-02-11 2008-07-17 Dana-Farber Cancer Institute, Inc., Boston Identifizierung von antigenen peptiden durch zytotoxische t-lymphozyten aktiviert von dendritischen zellhybriden
US20030165483A1 (en) * 2000-07-10 2003-09-04 Ulrich Zimmermann Method for the modification of biological cells
ATE396691T1 (de) 2001-02-20 2008-06-15 Ortho Mcneil Pharm Inc Zelltherapieverfahren für die behandlung von tumoren

Also Published As

Publication number Publication date
IL219223A0 (en) 2012-06-28
CA2698079A1 (en) 2002-08-29
EP2848255B1 (en) 2017-08-23
EP1377251A2 (en) 2004-01-07
CN1571834B (zh) 2013-03-20
IL219223B (en) 2018-05-31
NO334885B1 (no) 2014-06-30
HUP0402656A3 (en) 2012-03-28
PT1377251E (pt) 2008-08-05
EP1377251B1 (en) 2008-05-28
ATE396691T1 (de) 2008-06-15
EP2016930B1 (en) 2014-10-15
ZA200307327B (en) 2005-03-30
IL157366A (en) 2013-04-30
CN1571834A (zh) 2005-01-26
KR100962544B1 (ko) 2010-06-14
JP2012097117A (ja) 2012-05-24
BR0207399A (pt) 2004-10-26
KR20030077029A (ko) 2003-09-29
HK1058485A1 (en) 2004-05-21
ES2643582T3 (es) 2017-11-23
DE60226853D1 (de) 2008-07-10
PL369971A1 (pl) 2005-05-02
KR20090061081A (ko) 2009-06-15
KR100971266B1 (ko) 2010-07-20
IL157366A0 (en) 2004-02-19
JP2010222352A (ja) 2010-10-07
EP2016930A3 (en) 2009-09-02
JP2006510567A (ja) 2006-03-30
CA2698079C (en) 2015-01-13
US20030077248A1 (en) 2003-04-24
EP2016930A2 (en) 2009-01-21
MXPA03007503A (es) 2004-10-15
WO2002065992A3 (en) 2003-02-13
HK1208376A1 (en) 2016-03-04
NO20033674D0 (no) 2003-08-19
CA2438754A1 (en) 2002-08-29
CA2438754C (en) 2014-10-07
PL206976B1 (pl) 2010-10-29
ES2306771T3 (es) 2008-11-16
JP5634415B2 (ja) 2014-12-03
NZ527683A (en) 2006-06-30
HUP0402656A2 (hu) 2005-03-29
EP2848255A1 (en) 2015-03-18
EP1377251A4 (en) 2006-01-11
EA013944B1 (ru) 2010-08-30
US9222071B2 (en) 2015-12-29
DK2016930T3 (en) 2014-12-08
WO2002065992A2 (en) 2002-08-29
US20090305418A1 (en) 2009-12-10
NO20033674L (no) 2003-10-17

Similar Documents

Publication Publication Date Title
EA200300815A1 (ru) Способ клеточной терапии для лечения опухолей
EP1470821A3 (en) Cell therapy method for the treatment of tumours
Gilhar et al. Melanocyte-associated T cell epitopes can function as autoantigens for transfer of alopecia areata to human scalp explants on Prkdcscid mice
Masteller et al. Antigen-specific regulatory T cells—ex vivo expansion and therapeutic potential
Itoª et al. Immune privilege and the skin
Bremers et al. Immunology and immunotherapy of human cancer: present concepts and clinical developments
PT900380E (pt) Metodos para seleccionar e produzir epitopos peptidicos de celulas t e vacinas que incorporam os referidos epitopos seleccionados
WO2000061184A3 (en) Dry formulation for transcutaneous immunization
CY1110235T1 (el) Χρηση αλλογενετικων κυτταρικων γραμμων για τη φορτωση κυτταρων που εμφανιζουν αντιγονο για την προκληση ή εξαλειψη ανοσολογικων απαντησεων
CY1113044T1 (el) Παραλλαγματα αντιγονου αρχεγονων κυτταρων προστατη (psca) και υποαλληλουχιες εξ αυτων
ATE432085T1 (de) Stimulationsfaktor für dendriten
ATE491465T1 (de) Verfahren zur gewinnung aktivierter t-zellen und mit antigen-inkubierten antigen-präsentierender zellen
DE69839273D1 (de) Krebs immuntherapie mit semi-allogenen zellen
Laumbacher et al. Activated monocytes prime naïve T cells against autologous cancer: vigorous cancer destruction in vitro and in vivo
Berger et al. Circulation and homing of melanoma‐reactive T cells to both cutaneous and visceral metastases after vaccination with monocyte‐derived dendritic cells
Merimsky et al. Vitiligo-and melanoma-associated hypopigmentation: a similar appearance but a different mechanism
Massé et al. Increased expression of inducible HSP70 in apoptotic cells is correlated with their efficacy for antitumor vaccine therapy
Slovin et al. Immunological approaches for the treatment of prostate cancer
PT1025849E (pt) Metodos para deteccao e tratamento de individuos tendo celulas anormais que expressam antigenios do peptideo hla-a2/tirosinase
CA2399816A1 (en) A universal vaccine and method for treating cancer employing telomerase reverse transcriptase
Chatenoud Natural and induced T CD4+ CD25+ FOXP3+ regulatory T cells
HUP9800613A2 (hu) Humán Fas-antigén elleni humanizált antitest
DE69821506D1 (de) Verwendung einer chemisch stabilisierten chloritlösung zur inhibition der antigenspezifischen immunantwort
DK0837672T3 (da) Præparationer og fremgangsmåder til behandling af T-cellemedierede sygdomme
Chen What's new about the mechanism of methotrexate action in psoriasis?

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM RU